Clinical OMICS

MAY-JUN 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1117801

Contents of this Issue

Navigation

Page 36 of 50

www.clinicalomics.com May/June 2019 Clinical OMICs 35 known drug-resistant bacterium. "One of the problems is that we have not had the rapid methods to be able to identify the bacterium that the patient is infected with and, most importantly, determine if it is resistant to any antibiotics before, or at least very soon after, the patient is actually given an antibiotic," Taylor noted. "The patient who is on the wrong antibiotic, therefore, con- tinues to be infected and can transmit the infection to others and the environment." That's where the com- bined technologies of OpGen and ILÚM come in. Both have tackled similar issues—together and sep- arately—over the past few years. A notable collabora- tion between the two com- panies was the creation of an antimicrobial steward- ship and infection preven- tion and control technology that could be deployed in middle and lower income markets. Developed under a one- year $860,000 grant from the CDC, the smartphone-based clinical decision support solution was rolled out in three Colombian hospitals in 2017 and is still running today. Under the new pilot with New York, OpGen is provid- ing its Acuitas AMR gene panel for rapid detection of mul- tidrug-resistant bacterial pathogens, along with its Acuitas Lighthouse software for pathogen tracking. ILÚM pro- vides the technology backbone that will pull data from the state's network of HIEs to collect, in near real time, data that includes laboratory test results, pharmacy orders, and admissions, discharges, and transfers (ADT). Paul Edwards, managing director and CEO of ILÚM, views the pilot project as one that brings a precision medi- cine approach to managing CREs and other antibiotic resis- tant pathogens. Its goal is to identify individual patients infected with a drug-resistant bacterium, get them on the most effective drug for treating that specific bug, while also proactively isolating the patient to prevent further spread of the bacterium, not just within a single hospital or network, but within the entire public health system. "If you get to a point where you can help a physician know which antibiotic will work by the time the second dose is due—which is not something you can do today—you will change dramatically resistant mechanisms, you will change patient outcomes, and you will change hospital economics," Edwards told Clinical OMICs. Statewide effort The pilot project fits within a larger framework in the state that is tasked with tackling the health threat posed by anti- biotic resistance and managed under the NYS Antimicrobial Resistance Prevention and Control Task Force. One effort called STARR (NY STop Antibiotic Resistance Roadmap) created a series of recommendations last year the state can take to aid hospitals and health systems reduce the spread and prevalence of AR pathogens. "From the Department of Health perspective, it is our understanding that they are hoping to build a digital health (continued on next page) Evan Jones CEO, OpGen urfinguss / iStock / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2019